Tailor-made treatment for prevention of hepatitis after liver transplantation.

2016 Fiscal Year Final Research Report

• Project/Area Number: 24591876
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Mie University
• Principal Investigator: Usui Masanobu 三重大学, 医学部附属病院, 准教授 (10378341)
• Project Period (FY): 2012-04-01 – 2017-03-31
• Keywords: 肝移植 / 肝炎ウィルス / テーラーメード治療

Outline of Final Research Achievements

For the patients undergoing liver transplantation for hepatitis B virus (HBV)-related diseases, hepatitis B immunoglobulin (HBIG) should be administered to prevent reinfection. Because HBIG is highly expensive, an alternative strategy using HBV vaccination has been made in an attempt to discontinue use of HBIG. The ratio of male/female was 13/1 (median age: 55 years; range: 37 years to 67 years). The median follow-up time was 102 months (range: approximately 14 months to 148 months). All 14 patients were free of HBV recurrence. HBIG-free status could be achieved in 9 patients (64.3%) during the treatment period for more than 50 months after beginning of HBV vaccination, of whom 5 (35.7%) became HBV vaccine-free. T-cell proliferation was confirmed by fact that the stimulation index ranged from 2.34 to 5.2 in the patients who were HBIG-free.Long-term HBV vaccination after LT is a useful and effective treatment in preventing HBV recurrence, allowing the discontinuation of HBIG treatment.

Free Research Field

肝胆膵・移植外科